Compare Valero Energy Corporation (VLO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Valero Energy Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Valero Energy Corporation trades at $314.5 (market cap $93.03B), while Vertex Pharmaceuticals Incorporated trades at $478.11 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Valero Energy Corporation pays a 1.53% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| VLO | VRTX | |
|---|---|---|
Market Cap | $93.03B | $121.95B |
Sector | Energy | Health |
52-Week High | $313.31 | $529.59 |
52-Week Low | $131.77 | $366.54 |
Enterprise Value | $98.79B | $116.69B |
Dividend Yield | 1.53% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Valero Energy (VLO) trades at $314.80, up 1.66% today and near its 52-week high, with a bullish technical outlook supported by strong moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 expected at $10.13 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 3.37%, while valuation ratios like P/E of 22.89 and P/S of 0.77 reflect moderate pricing relative to peers. Recent news highlights robust refining margins and dividend declarations of $1.20 per share.
VLO's outlook is positive due to elevated crack spreads and strong fuel demand, though revenue declines pose a risk. Analyst consensus is bullish with a $285.38 price target, but high RSI levels suggest potential near-term pullbacks. Investment appeal lies in earnings momentum and shareholder returns, balanced against exposure to volatile energy markets and refining margins.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
